Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments beta cell mass via activation of beta cell proliferation and islet neogenesis. We examined whether GLP-1 receptor signaling modifies the cellular susceptibility to apoptosis. Mice administered streptozotocin (STZ), an agent known to induce beta cell apoptosis, exhibit sustained improvement in glycemic control and increased levels of plasma insulin with concomitant administration of the GLP-1 agonist exendin-4 (Ex-4). Blood glucose remained significantly lower for weeks after cessation of exendin-4. STZ induced beta cell apoptosis, which was significantly reduced by co-administration of Ex-4. Conversely, mice with a targeted disruption of the GLP-1 receptor gene exhibited increased beta cell apoptosis after STZ administration. Exendin-4 directly reduced cytokine-induced apoptosis in purified rat beta cells exposed to interleukin 1beta, tumor necrosis fator alpha, and interferon gamma in vitro. Furthermore, Ex-4-treated BHK-GLP-1R cells exhibited significantly increased cell viability, reduced caspase activity, and decreased cleavage of beta-catenin after treatment with cycloheximide in vitro. These findings demonstrate that GLP-1 receptor signaling directly modifies the susceptibility to apoptotic injury, and provides a new potential mechanism linking GLP-1 receptor activation to preservation or enhancement of beta cell mass in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies to date that have reported an increase in β-cell mass with glucagon-like peptide 1 (GLP-1)-1 based therapies were undertaken in young rodents (17–21).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [19]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
Self-citationMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Induction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Self-citationDeacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Self-citationSherwood, N. M., Krueckl, S. L., & McRory, J. E. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0414 · Cited by 726
Research works printed but not linked: 7
- de la Tour, 2001, Mol. Endocrinol., 15, 476
- Boushey, 2001, Cancer Res., 61, 687
- Trumper, 2001, Mol. Endocrinol., 15, 1559
- Drucker, 1997, Am. J. Physiol., 273, G1252
- Drucker, 2001, J. Clin. Endocrinol. Metab., 86, 1759
- Bregenholt, 2001, 50, 125
- Sherwood, 2000, Endocr. Rev., 21, 619
Cited by
Items 101–200 of 597
Incretin effect: GLP-1, GIP, DPP4
Kazakos, K. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70011-0 · Cited by 153
Kiba, T. (2004) · Pancreas · doi:10.1097/00006676-200408000-00019 · Cited by 126
Glucagon‐like peptide 1 receptor stimulation as a means of neuroprotection
Harkavyi, A., & Whitton, P. S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00486.x · Cited by 125
“Thus, EX-4 shows clear protection of b-cells incubated with either interleukin-1-beta (IL-1b), tumour necrosis factor alpha (TNF-a) or interferon gamma (IFN-g) as well as combinations of these cytokines (Li et al., 2003).”
BackgroundBenefits and limitations of reducing glucagon action for the treatment of type 2 diabetes
Ali, S., & Drucker, D. J. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90887.2008 · Cited by 124
Self-citationSaxagliptin: A novel antiparkinsonian approach
Nassar, N. N., Al‐Shorbagy, M. Y., Arab, H. H., & Abdallah, D. M. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.007 · Cited by 128
Bouzakri, K., Plomgaard, P., Berney, T., Donath, M. Y., Pedersen, B. K., & Halban, P. A. (2011) · Diabetes · doi:10.2337/db10-1178 · Cited by 122
Self-citationIncretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
Takeda, Y., Fujita, Y., Honjo, J., Yanagimachi, T., Sakagami, H., Takiyama, Y., Makino, Y., Abiko, A., Kieffer, T. J., & Haneda, M. (2011) · Diabetologia · doi:10.1007/s00125-011-2365-4 · Cited by 126
“In addition to the common antiapoptotic pathways of GLP-1 and GIP signalling [6, 26–31], different pathways [32–36] may promote additive”
BackgroundResultThe Glucagon‐Like Peptides: Pleiotropic Regulators of Nutrient Homeostasis
BRUBAKER, P. L. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1317.006 · Cited by 111
The effects of glucagon‐like peptide‐1 on the beta cell
Vilsbøll, T. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01073.x · Cited by 115
GLP-1/exendin-4 facilitates β-cell neogenesis in rat and human pancreatic ducts
Xu, G., Kaneto, H., Lopez-Avalos, M. D., Weir, G. C., & Bonner-Weir, S. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.11.007 · Cited by 115
The glucagon-like peptides: a double-edged therapeutic sword?
Perry, T., & Greig, N. H. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00160-3 · Cited by 122
Parkes, D. G., Mace, K. F., & Trautmann, M. E. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.741580 · Cited by 108
“demonstrated sustained improvement in glycemic control and increased plasma insulin levels with concomitant administration of exenatide to streptozotocin-treated mice [71].”
BackgroundTherapy in the Early Stage: Incretins
Cernea, S., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s223 · Cited by 110
Dong, C. X., Zhao, W., Solomon, C., Rowland, K. J., Ackerley, C., Robine, S., Holzenberger, M., Gonska, T., & Brubaker, P. L. (2014) · Endocrinology · doi:10.1210/en.2013-1871 · Cited by 108
“To develop a model of altered barrier function, control and KO animals were first subjected to multiple low-dose injections of streptozotocin, using a protocol known to induce diabetes in normal C57BL/6 mice (27).”
MethodBeneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice
Himeno, T., Kamiya, H., Naruse, K., Harada, N., Ozaki, N., Seino, Y., Shibata, T., Kondo, M., Kato, J., Okawa, T., et al. (2011) · Diabetes · doi:10.2337/db10-1462 · Cited by 112
Self-citationFailure of Transplanted Bone Marrow Cells to Adopt a Pancreatic β-Cell Fate
Taneera, J., Rosengren, A. H., Renström, E., Nygren, J., Serup, P., Rorsman, P., & Jacobsen, S. E. W. (2006) · Diabetes · doi:10.2337/diabetes.55.02.06.db05-1212 · Cited by 124
Exendin-4 modulates diabetes onset in nonobese diabetic mice
Hadjiyanni, I., Baggio, L. L., Poussier, P., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2007-1137 · Cited by 110
Self-citationGLP-1, the Gut-Brain, and Brain-Periphery Axes
Cabou, C., & Burcelin, R. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.418 · Cited by 110
“Furthermore, GLP-1 increases β-cell mass by stimulating proliferation, inducing islet neogenesis, and inhibiting apoptosis [24-25].”
BackgroundNing, Y., O’Neill, K., Lan, H., Pang, L., Shan, L. X., Hawes, B. E., & Hedrick, J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.337 · Cited by 108
“For example, it has been shown that GLP-1R signalling can augment b cell mass in rodents via activation of b cell proliferation and neogenesis (Li et al., 2003).”
BackgroundEmerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1
Riddle, M. C., & Drucker, D. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1267 · Cited by 109
Self-citationTargeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Salehi, M., Aulinger, B. A., & D'Alessio, D. A. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0031 · Cited by 109
Wideman, R. D., Yu, I. L. Y., Webber, T. D., Verchere, C. B., Johnson, J. D., Cheung, A. T., & Kieffer, T. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600655103 · Cited by 108
Maida, A., Lovshin, J. A., Baggio, L. L., & Drucker, D. J. (2008) · Endocrinology · doi:10.1210/en.2008-0336 · Cited by 103
Self-citationBriyal, S., Shah, S. Z., & Gulati, A. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.09.064 · Cited by 109
Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors
Holst, J. J. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.9.1.155 · Cited by 103
GLP-1 based therapy for type 2 diabetes
Arulmozhi, D. K., & Portha, B. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2006.01.003 · Cited by 115
Glucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Mizokami, A., Yasutake, Y., Higashi, S., Kawakubo‐Yasukochi, T., Chishaki, S., Takahashi, I., Takeuchi, H., & Hirata, M. (2014) · Bone · doi:10.1016/j.bone.2014.09.006 · Cited by 100
“Moreover, we (Mizokami A, Kawakubo-Yasukochi T, Yasutake Y, and Hirata M, manuscript in preparation) found that long-term oral administration of GluOC had little effect on glucose tolerance in GLP-1 receptor knockout mice [32–35], indicating that GLP-1 plays a key role in the improvement in glucose utilization induced…”
BackgroundExenatide inhibits β-cell apoptosis by decreasing thioredoxin-interacting protein
Chen, J., Couto, F. M., Minn, A. H., & Shalev, A. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.027 · Cited by 108
GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions
Yu, J. H., Park, S. Y., Lee, D. Y., Kim, N. H., & Seo, J. A. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.001 · Cited by 104
Liu, Z., Stanojevic, V., Avadhani, S., Yano, T., & Habener, J. F. (2011) · Diabetologia · doi:10.1007/s00125-011-2181-x · Cited by 93
“The effect of SDF-1 on GLP-1 production is an important finding because GLP-1 is known to stimulate the growth [14, 26] and promote the survival [27, 28] of beta cells.”
BackgroundRole of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus
León, D. D. D., Crutchlow, M. F., Ham, J.-Y. N., & Stoffers, D. A. (2006) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.07.011 · Cited by 94
Calara, F., Taylor, K., Han, J., Zabala, E., Carr, E. M., Wintle, M. E., & Fineman, M. S. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.02.008 · Cited by 100
Glucagon-like peptide 1 agonists and the development and growth of pancreatic β-cells
List, J. F., & Habener, J. F. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00007.2004 · Cited by 94
Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes
Ravassa, S., Zudaire, A., Carr, R. D., & Díez, J. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00885.2010 · Cited by 91
Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential
Sinclair, E. M., & Drucker, D. J. (2005) · Physiology · doi:10.1152/physiol.00030.2005 · Cited by 87
Self-citationBaggio, L. L., Kim, J.-G., & Drucker, D. J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s205 · Cited by 91
Self-citationMukai, E., Fujimoto, S., Sato, H., Oneyama, C., Kominato, R., Sato, Y., Sasaki, M., Nishi, Y., Okada, M., & Inagaki, N. (2011) · Diabetes · doi:10.2337/db10-0021 · Cited by 92
Class II G Protein-Coupled Receptors and Their Ligands in Neuronal Function and Protection
Martin, B., de Maturana, R. L., Brenneman, R., Walent, T., Mattson, M. P., & Maudsley, S. R. (2005) · NeuroMolecular Medicine · doi:10.1385/nmm:7:1-2:003 · Cited by 100
“Activation of GLP-1 receptor signalling can also promote proliferative and anti-apoptotic actions in the endocrine pancreas, providing a potential opportunity for interventions directed at expanding β-cell mass in subjects with diabetes (Li et al., 2003; Drucker, 2003).”
BackgroundHu, Y., Riesland, L., Paterson, A. J., & Kudlow, J. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401547200 · Cited by 95
Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
Shyangdan, D. S., Royle, P. L., Clar, C., Sharma, P., & Waugh, N. R. (2010) · BMC Endocrine Disorders · doi:10.1186/1472-6823-10-20 · Cited by 88
“There is some evidence from animal models that the GLP-1 analogues increases pancreatic islet beta-cell mass [13] and reduce beta-cell apoptosis [14,15].”
Backgroundβ-cell apoptosis in type 2 diabetes: quantitative and functional consequences
Lupi, R., & Prato, S. D. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73396-2 · Cited by 105
Islet transplantation outcomes in mice are better with fresh islets and exendin-4 treatment
King, A., Hollister‐Lock, J., Xu, G., Bonner‐Weir, S., & Weir, G. C. (2005) · Diabetologia · doi:10.1007/s00125-005-1922-0 · Cited by 95
“The effect of exendin-4 on the islets could be due to the proliferative and anti-apoptotic effects that this peptide has on beta cells [6–8].”
BackgroundIncreased Pancreatic β-Cell Proliferation Mediated by CREB Binding Protein Gene Activation
Hussain, M. A., Porras, D. L., Rowe, M. H., West, J. R., Song, W.-J., Schreiber, W. E., & Wondisford, F. E. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02353-05 · Cited by 88
“... mechanisms may lead to an increase in -cell mass: (i) neogenesis from nonendocrine pancreatic tissue, such as pancreatic-duct epithelium (2, 3, 27, 28), pancreatic acinar cells ( cells derived from non- cells) (3, 38, 39), or undifferentiated cells within the islet (1, 9, 15, 44); (ii) proliferation of cells ( cel…”
BackgroundGlucagon and Glucagon-Like Peptide Receptors as Drug Targets
Estall, J., & Drucker, D. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206776873671 · Cited by 88
“More recently, considerable experimental evidence indicates that activation of GLP-1R signaling can also protect β−cells from programmed cell death (apoptosis) and stimulate β−cell proliferation in cultured rodent and human islets and in rodent models of diabetes [95-99].”
BackgroundSelf-citationMaida, A., Hansotia, T., Longuet, C., Seino, Y., & Drucker, D. J. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.09.004 · Cited by 98
Self-citationGlucolipotoxicity and beta cells in type 2 diabetes mellitus: Target for durable therapy?
van Raalte, D. H., & Diamant, M. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70012-2 · Cited by 101
Strader, A. D., Clausen, T. R., Goodin, S., & Wendt, D. (2008) · Obesity Surgery · doi:10.1007/s11695-008-9754-x · Cited by 95
Portha, B., Tourrel-Cuzin, C., & Movassat, J. (2011) · Experimental Diabetes Research · doi:10.1155/2011/376509 · Cited by 85
“A role for endogenous GLP-1 in prevention of beta-cell death was demonstrated by the increased susceptibility to streptozotocin-induced apoptosis in GLP-1R knockout mice; conversely, streptozotocininduced apoptosis was significantly reduced by coadministration of Ex-4 [67].”
BackgroundBan, K., Hui, S., Drucker, D. J., & Husain, M. (2009) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2009.04.001 · Cited by 88
Self-citationVarney, M. J., & Benovic, J. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001015 · Cited by 90
Liu, W. J., Jin, H. Y., Lee, K. A., Xie, S. H., Baek, H. S., & Park, T. S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01272.x · Cited by 84
“GLP-1 and a receptor agonist offer protective effects in neuronal cells in addition to in insulinsecreting cells, by coupling to trophic and antiapoptotic signalling pathways (Perry et al., 2002a; 2003; Li et al., 2003).”
BackgroundPhysiology and Emerging Biochemistry of the Glucagon-Like Peptide-1 Receptor
Willard, F. S., & Sloop, K. W. (2012) · Experimental Diabetes Research · doi:10.1155/2012/470851 · Cited by 79
“A key point to contextualize these studies is that although numerous reports in rodents show positive effects of GLP-1 or exendin4 on pancreatic β-cell replication, β-cell mass, and function in preclinical models [102, 103], less data are available regarding GLP-1 agonist modulation of β-cell apoptosis or neogenesis i…”
BackgroundFroud, T., Faradji, R. N., Pileggi, A., Messinger, S., Baidal, D. A., Ponte, G. M., Cure, P. E., Monroy, K., Mendez, A., Selvaggi, G., et al. (2008) · Transplantation · doi:10.1097/tp.0b013e31817c4ab3 · Cited by 84
“There is a wealth of evidence that GLP-1 and GLP-1 receptor agonists can improve metabolic control (33,35,36), reduce apoptosis ( 37 ), and increase islet neogenesis and regeneration in a variety of animal models of diabetes (19, 20, 38–41).Theinterestingquestionremainswhetherlong-term administration can increase isle…”
BackgroundmiR-204 Controls Glucagon-Like Peptide 1 Receptor Expression and Agonist Function
Jo, S., Chen, J., Xu, G., Grayson, T. B., Thielen, L. A., & Shalev, A. (2018) · Diabetes · doi:10.2337/db17-0506 · Cited by 80
Finan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 81
Yang, J., Campitelli, J., Hu, G., Lin, Y., Luo, J. J., & Xue, C. (2007) · Life Sciences · doi:10.1016/j.lfs.2007.04.040 · Cited by 94
Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors
Gong, N., Fan, H. J., Ma, A., Xiao, Q., & Wang, Y. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.04.007 · Cited by 83
“The endogenous incretin glucagon-like peptide-1 (GLP-1) and exogenous exenatide have biological actions in the pancreas, such as stimulating glucose-dependent insulin synthesis and secretion, decreasing glucagon levels and notably altering b-cell proliferation and apoptosis (Baggio and Drucker, 2007; Li et al., 2003).”
Katagiri, D., Hamasaki, Y., Doi, K., Okamoto, K., Negishi, K., Nangaku, M., & Noiri, E. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013020134 · Cited by 80
Wang, H., Iezzi, M., Theander, S. S., Antinozzi, P. A., Gauthier, B. R., Halban, P. A., & Wollheim, C. B. (2005) · Diabetologia · doi:10.1007/s00125-005-1692-8 · Cited by 89
“GLP-1R plays an important role in the regulation of beta cell neogenesis, development, differentiation and survival as well as insulin secretion [50, 51, 67–69].”
Self-citationSelective Ablation of Peptide YY Cells in Adult Mice Reveals Their Role in Beta Cell Survival
Sam, A. H., Gunner, D. J., King, A., Persaud, S. J., Brooks, L. J., Hostomska, K., Ford, H. E., Liu, B., Ghatei, M. A., Bloom, S. R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.047 · Cited by 80
Zhang, J., Tokui, Y., Yamagata, K., Kozawa, J., Sayama, K., Iwahashi, H., Okita, K., Miuchi, M., Konya, H., Hamaguchi, T., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0737-6 · Cited by 84
“More recent studies have demonstrated that administration of GLP-1 inhibits beta cell apoptosis via the PI3-K–PKB signalling pathway [10–12].”
BackgroundTimper, K., Dalmas, E., Dror, E., Rütti, S., Thienel, C., Sauter, N. S., Bouzakri, K., Bédat, B., Pattou, F., Kerr-Conte, J., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.003 · Cited by 67
Costes, S., Bertrand, G., & Ravier, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105303 · Cited by 81
Characterization of Zinc Influx Transporters (ZIPs) in Pancreatic β Cells
Liu, Y., Batchuluun, B., Ho, L., Zhu, D. Y., Prentice, K. J., Bhattacharjee, A., Zhang, M., Pourasgari, F., Hardy, A. B., Taylor, K. M., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.640524 · Cited by 86
“Effect of ZIP6 and ZIP7 on GLP-1-mediated Signaling— GLP-1, acting via the GLP-1 receptor (GLP-1R), has a well established stimulatory effect on glucose-induced insulin secretion from pancreatic islets (56), and it protects rodent cells from cytokine-induced apoptosis (57).”
BackgroundDipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney
Joo, K. W., Kim, S., Ahn, S. Y., Chin, H. J., Chae, D., Lee, J., Han, J. S., & Na, K. Y. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-98 · Cited by 82
“An anti-apoptotic effect mediated by GLP-1R has been suggested in various tissues, including pancreatic beta cells [32], neurons [33], and cardiomyocytes [12].”
BackgroundGlucagon-like peptide-1 and glucagon-like peptide-2
Baggio, L. L., & Drucker, D. J. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.001 · Cited by 84
Self-citationGlucagon-like peptide 1: evolution of an incretin into a treatment for diabetes
D’Alessio, D. A., & Vahl, T. P. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00014.2004 · Cited by 80
Huang, H.-J., Chen, Y.-H., Liang, K.-C., Jheng, Y.-S., Jhao, J.-J., Su, M.-T., Lee-Chen, G.-J., & Hsieh-Li, H. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039656 · Cited by 72
Girard, J. R. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.09.001 · Cited by 85
Proglucagon-Derived Peptides as Therapeutics
Lafferty, R. A., O’Harte, F. P. M., Irwin, N., Gault, V. A., & Flatt, P. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.689678 · Cited by 71
GLP-1 inhibition of pancreatic islet cell apoptosis
Urusova, I. A., Farilla, L., Hui, H., D'Amico, E., & Perfetti, R. (2003) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2003.11.006 · Cited by 77
Exendin-4 Improves β-Cell Function in Autophagy-Deficient β-Cells
Abe, H., Uchida, T., Hara, A., Mizukami, H., Komiya, K., Koike, M., Shigihara, N., Toyofuku, Y., Ogihara, T., Uchiyama, Y., et al. (2013) · Endocrinology · doi:10.1210/en.2013-1578 · Cited by 71
Wideman, R. D., Covey, S. D., Webb, G. C., Drucker, D. J., & Kieffer, T. J. (2007) · Diabetes · doi:10.2337/db07-0563 · Cited by 70
Self-citationKapodistria, K., Tsilibary, E., Kotsopoulou, E., Moustardas, P., & Kitsiou, P. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13259 · Cited by 67
Lavine, J. A., Raess, P. W., Stapleton, D. S., Rabaglia, M. E., Suhonen, J. I., Schueler, K. L., Koltes, J. E., Dawson, J. A., Yandell, B. S., Samuelson, L. C., et al. (2010) · Endocrinology · doi:10.1210/en.2010-0233 · Cited by 70
Greig, N. H., Tweedie, D., Rachmany, L., Li, Y., Rubovitch, V., Schreiber, S., Chiang, Y.-H., Hoffer, B. J., Miller, J., Lahiri, D. K., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.12.011 · Cited by 70
“Expanding upon our prior interest of GLP-1 and Ex-4 in T2DM, their insulinotropic and antiapoptotic actions [93,94,97,98], the structure-activity relation of their amino acid sequence [99-101], and their translation to clinic [102,75], we hypothesized that GLP-1R stimulation in brain would provide neurotrophic/protect…”
Self-citationAnti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury
Higashijima, Y., Tanaka, T., Yamaguchi, J., Tanaka, S., & Nangaku, M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00590.2014 · Cited by 69
Deciphering Metabolic Messages From the Gut Drives Therapeutic Innovation: The 2014 Banting Lecture
Drucker, D. J. (2015) · Diabetes · doi:10.2337/db14-1514 · Cited by 67
Self-citationHinke, S. A., Hellemans, K., & Schuit, F. C. (2004) · The Journal of Physiology · doi:10.1113/jphysiol.2004.064881 · Cited by 81
“At the other extreme of the time scale, requiring days to weeks, glucose and also incretins have been proposed to determine the size of the pancreatic β cell pool by affecting the rates at which β cells are generated and destroyed, respectively, by neogenesis and apoptosis (Hoorens et al. 1996; Jonas et al. 1999; Bonn…”
BackgroundNatalicchio, A., Labarbuta, R., Tortosa, F., Biondi, G., Marrano, N., Peschechera, A., Carchia, E., Orlando, M. R., Leonardini, A., Cignarelli, A., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-3028-4 · Cited by 79
“Administration of GLP-1 was associated with proliferative and antiapoptotic effects in both endocrine and exocrine compartments of the pancreas [43, 44], and significantly reduced apoptotic beta cells in experimental diabetes models [45].”
BackgroundRepeated administration of exendin-4 reduces focal cerebral ischemia-induced infarction in rats
Briyal, S., Gulati, K., & Gulati, A. (2011) · Brain Research · doi:10.1016/j.brainres.2011.10.026 · Cited by 71
Preservation of β-cell function by targeting β-cell mass
DEKONING, E., Bonner‐Weir, S., & Rabelink, T. J. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.02.001 · Cited by 84
Maiztegui, B., Borelli, M. I., Madrid, V., Zotto, H. H. D., Raschia, M. A., Francini, F., Massa, M. L., Flores, L. E., Rebolledo, O. R., & Gagliardino, J. J. (2010) · Clinical Science · doi:10.1042/cs20100372 · Cited by 73
Holz, G. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826165 · Cited by 69
Hypoxia as a target for tissue specific gene therapy
Rhim, T., Lee, D. Y., & Lee, M. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.05.021 · Cited by 66
Ning, Y., Wei, Z. C., Fu, Z., Jiang, J. Z., Liu, D., Belardinelli, L., & Dhalla, A. K. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.176396 · Cited by 75
Sharma, R., & Soman, S. S. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.11.041 · Cited by 66
Paracrine signaling in islet function and survival
Hartig, S. M., & Cox, A. R. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01887-x · Cited by 70
Shin, S., Le Lay, J., Everett, L. J., Gupta, R., Rafiq, K., & Kaestner, K. H. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.08.001 · Cited by 62
“Furthermore, it has been postulated that exendin-4 protects b-cells from cytokine-induced apoptosis [15,16,41,42], while previous overexpression and dominant-negative approaches have indicated that CREB might be required for this effect on b-cell survival [7,9].”
BackgroundExenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus
Briones, M., & Bajaj, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.8.1055 · Cited by 63
Seghieri, G., Anichini, Cosimi, S., Carlo, D., Bellis, D., Franconi, Orsini, P., & Baccetti (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s42729 · Cited by 63
Glucagon-Like Peptide-2 Receptor Modulates Islet Adaptation to Metabolic Stress in the ob/ob Mouse
Bahrami, J., Longuet, C., Baggio, L. L., Li, K., & Drucker, D. J. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.006 · Cited by 63
Self-citationMolecular Mechanisms Underlying the Cardiovascular Benefits of SGLT2i and GLP-1RA
Khat, D. Z., & Husain, M. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1011-7 · Cited by 66
Liganded Thyroid Hormone Receptor-α Enhances Proliferation of Pancreatic β-Cells
Furuya, F., Shimura, H., Yamashita, S., Endo, T., & Kobayashi, T. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.100222 · Cited by 69
Arakawa, M., Ebato, C., Mita, T., Hirose, T., Kawamori, R., Fujitani, Y., & Watada, H. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.10.054 · Cited by 65
Natalicchio, A., De Stefano, F., Orlando, M. R., Melchiorre, M., Leonardini, A., Cignarelli, A., Labarbuta, R., Marchetti, P., Perrini, S., Laviola, L., et al. (2010) · Endocrinology · doi:10.1210/en.2009-1166 · Cited by 60
Diabetes as a disease of endoplasmic reticulum stress
Thomas, S. E., Dalton, L. E., Daly, M., Malzer, E., & Marciniak, S. J. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1132 · Cited by 65
“Exendin-4 is an agonist at this receptor and has been shown to enhance insulin synthesis and secretion, whilst promoting β-cell survival [62–64].”
BackgroundThe DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats
Duttaroy, A., Voelker, F. A., Merriam, K., Zhang, X., Ren, X., Subramanian, K., Hughes, T. E., & Burkey, B. F. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.062 · Cited by 75
Metadata
- Authors
- Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 1
- Pages
- 471-478
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2149502431
- Cited by
- 589
- References
- 64
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 9 · 2023: 6 · 2022: 10 · 2021: 12 · 2020: 7 · 2019: 17 · 2018: 7 · 2017: 16 · 2016: 26 · 2015: 34 · 2014: 41 · 2013: 45 · 2012: 33
- FWCI
- 26.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6497 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- GLP-1 receptor, beta-cell apoptosis, exendin-4, streptozotocin, beta-cell mass, cytokine-induced apoptosis, IL-1β, TNF-α, interferon-gamma, caspase activity, GLP-1 receptor signaling, type 1 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Blood Glucose, Cell Line, Cell Survival, Cycloheximide, Cytoskeletal Proteins, Diabetes Mellitus, Experimental, Colforsin, Glucagon, Glucose Tolerance Test, Cricetinae, Insulin, Islets of Langerhans, Male, Mice, Inbred C57BL, Peptide Fragments, Peptides, Protein Precursors, Protein Synthesis Inhibitors, Streptozocin, Venoms, Signal Transduction, Trans-Activators, Cytokines, Rats, Wistar, Apoptosis, Receptors, Glucagon, Mice, Knockout, In Situ Nick-End Labeling, beta Catenin, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.